Wegovy vs Zepbound: Which GLP-1 Is Right for You?

Wegovy and Zepbound are the two prescription weight loss medications your doctor is most likely to consider. Both are FDA-approved specifically for chronic weight management. They\'re also chemically identical to their diabetes-approved siblings (Ozempic and Mounjaro) — just at higher doses and different labels. Here\'s the honest comparison.

The one-sentence version

Wegovy is high-dose semaglutide, FDA-approved for weight loss. Zepbound is tirzepatide (a newer dual-pathway drug), also FDA-approved for weight loss. Both are once-weekly injections. Zepbound tends to produce more weight loss on average; Wegovy has a longer real-world track record.

What Wegovy actually is

Wegovy is the brand name for semaglutide at the higher doses approved for weight management (up to 2.4mg weekly). It\'s the same molecule as Ozempic — just labeled for weight loss instead of type 2 diabetes. Wegovy activates GLP-1 receptors, reducing appetite, slowing gastric emptying, and improving how your body handles insulin.

Clinical trial results (STEP-1): average 14.9% body weight loss over 68 weeks at maximum dose. Real-world results vary — our Bloomington patients have reported losses from 15 to 50+ pounds.

What Zepbound actually is

Zepbound is the brand name for tirzepatide at doses approved for weight management (up to 15mg weekly). It\'s the same molecule as Mounjaro. Zepbound is a dual GLP-1 + GIP receptor agonist — it activates two hormone pathways instead of one, which is why it typically produces more weight loss than single-pathway GLP-1 drugs.

Clinical trial results (SURMOUNT-1): average body weight loss of 15% at 5mg, 19.5% at 10mg, and 22.5% at 15mg — all over 72 weeks. Highest sustained weight loss ever documented for a non-surgical intervention.

Wegovy vs Zepbound — head to head

Weight loss efficacy

Zepbound produces more weight loss on average in clinical trials. But averages aren\'t individuals. Some patients respond dramatically to Wegovy and only modestly to Zepbound (or vice versa). Which one works for you depends on how your body responds — something we monitor with weekly check-ins so we can pivot early if a medication isn\'t producing results.

Side effects

Side effect profiles are nearly identical. Both produce mild-to-moderate GI symptoms (nausea, reduced appetite, constipation, or diarrhea) during dose ramp-up. Zepbound\'s higher potency can produce slightly more intense titration symptoms, but with proper dose management most patients tolerate either drug well. See our full GLP-1 side effects guide for how we manage each symptom in clinic.

Insurance coverage

Coverage varies significantly. Some commercial plans cover Wegovy but not Zepbound; others cover Zepbound but not Wegovy; some cover neither for weight loss. We check your specific plan and offer transparent cash-pay alternatives if coverage falls short. Details in our insurance guide.

How we decide which one to prescribe

1. Starting BMI and weight loss goal. Patients with more to lose often benefit from Zepbound\'s higher weight-loss ceiling.
2. Prior GLP-1 experience. If Wegovy has been tried and plateaued, Zepbound is the logical next step.
3. Insurance coverage. If one is covered and the other isn\'t, that\'s a major practical factor.
4. Tolerance. Some patients tolerate GLP-1 alone better than a dual GLP-1+GIP.

For most patients starting from zero, we start with Wegovy — see how your body responds — and move to Zepbound later if needed. That approach uses the medication with more real-world track record first, then escalates only when it\'s warranted.

Bottom line for Twin Cities patients

If you\'re in Bloomington, Edina, Minneapolis, or anywhere in the Twin Cities and want a physician\'s recommendation for Wegovy vs Zepbound: book a free consultation. We\'ll review your history and recommend the medication we\'d want for our own family in your situation.